
Opinion|Videos|March 21, 2025
Postimmunotherapy Options in RCC: Latest Trial Data and Expert Perspectives on Rechallenge Strategies
Experts discuss key findings from the phase 3 CONTACT-03 trial investigating atezolizumab plus cabozantinib vs cabozantinib alone in inoperable advanced renal cell carcinoma (aRCC) after immune checkpoint inhibitor (ICI) treatment, along with insights from real-world data on sequencing strategies and the efficacy of tyrosine kinase inhibitors (TKIs) after prior ICI therapy.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Could you highlight key findings from the phase 3 CONTACT-03 trial investigating atezolizumab plus cabozantinib vs cabozantinib in inoperable aRCC after ICI treatment and other relevant studies?
- What insights do real-world data and experience provide about sequencing strategies and the efficacy of TKIs after prior ICI therapy?
- Real-world outcomes with cabozantinib after prior ICI
- Are there any patients in which you consider immunotherapy rechallenge after progression on initial ICI-based therapy? How might you differentiate between rechallenging with PD-L1 inhibitors vs CTLA-4-based approaches?
- What insights do emerging data, such as the TiNivo-3 trial, provide regarding this strategy? Phase 3 TiNivo-2 trial investigating tivozanib ± nivolumab after an ICI
Advertisement
Related to this article

The FDA approved giredestrant plus everolimus in ESR1-mutated breast cancer and neladalkib in ALK+ NSCLC, issued a CRL to ivonescimab, and more.

Daraxonrasib plus gemcitabine/nab-paclitaxel yielded a 60.7% ORR and 12.8-month median PFS in first-line metastatic pancreatic adenocarcinoma.

Sac-TMT improved OS vs treatment of physician’s choice in pretreated gastroesophageal adenocarcinoma, but TroFuse-015 missed its PFS secondary end point.

Gynecologic oncologists answer FAQs on LGSOC targeted therapy, PARP inhibitor maintenance, and emerging ADCs in ovarian cancer.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Jorge Cortes, MD, discusses response-based ponatinib dosing, mutation testing, and managing cardiovascular risk in resistant CML.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
3
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
4
Dr Leighl on HARMONi Survival Data and the FDA's Decision on Ivonescimab in Previously Treated EGFR-Mutated NSCLC
5



